Abstract: An electrical connection system for cell voltage monitoring in a fuel cell stack. The fuel cell stack comprises a plurality of layers and a plurality of electrically conductive connection tabs extending outwardly from at least one face of the stack. The electrically conductive connection tabs are each formed as a laterally extending free portion of a flexible sealing gasket. Other portions of the gasket are disposed to provide sealing engagement between at least two layers of the fuel cell stack. By using the gasket material to form such electrical connection tabs, rather than flow plates, the connection tabs are made flexible to make it easier to connect to standard arrays of connectors in connector assemblies.

Abstract: An electrical connection system for cell voltage monitoring in a fuel cell stack. The fuel cell stack comprises a plurality of layers and a plurality of electrically conductive connection tabs extending outwardly from at least one face of the stack. The electrically conductive connection tabs are each formed as a laterally extending free portion of a flexible sealing gasket. Other portions of the gasket are disposed to provide sealing engagement between at least two layers of the fuel cell stack. By using the gasket material to form such electrical connection tabs, rather than flow plates, the connection tabs are made flexible to make it easier to connect to standard arrays of connectors in connector assemblies.

Abstract: Device (10) for dispensing a pre-defined quantity of oil to an ear, comprising a nozzle (20) operably coupled to the vessel (12) containing oil (14), the nozzle (20) being adapted to be placed in the ear and capable of expelling the oil (14) from the vessel (12) when desired and permitting expulsion when the vessel (12) and/or device (10) is in a substantially upright or substantially inverted position. The present application also relates to a kit of parts for producing the device (10).

Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, wherein R1 represents C1-4 alkyl; R2 represents halo, C1-4 alkyl, C3-6 cycloalkyl, C3-6 cycloalkyloxy, —SO2(C1-4 alkyl), optionally substituted C1-4 alkyloxy, Het or —OHet; R3 represents a bicyclic group of the formula ?wherein X and Y are selected from C and N, provided that at least one is C; Ring A together with X and Y represents a 5- or 6-membered aromatic ring containing 0, 1, 2 or 3 nitrogen atoms in the ring; n is), 1 or 2 L represents a direct link, C1-4 alkylene or C1-4 alkoxyalkylene; R4 represents H, —NR5R6, C3-6 cycloalkyl, —OR7, Het1 or Het4; R5 and R6 are independently selected from H, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-4 alkylene, —SO2(C1-4 alkyl) and optionally substituted C1-4 alkyl R7 is selected from H, C1-4 alkyl, C1-4 alkoxyalkyl, C3-6cycloalkyl, Het2 and C1-4alkyl-Het3; R8 is H or C1-4 alkyl; Het, Het1, Het2 and Het3 independently represent an optionally substituted 4 to 7 membered saturat

Abstract: This invention relates to compounds of formula (I)

Abstract: Compounds of formula (I): 1

Abstract: Compounds of formula (I) and pharmaceutically-acceptable derivatives thereof, are matrix metalloprotease inhibitors, useful in treatment of conditions mediated by matrix metalloproteases, such as chronic dermal ulcers.